

The UK nationwide cardiorespiratory impact of the COVID-19 pandemic

First published: 02/05/2023

Last updated: 21/02/2024

Study

Planned

Administrative details

PURI

<https://redirect.ema.europa.eu/resource/104832>

EU PAS number

EUPAS104709

Study ID

104832

DARWIN EU® study

No

Study countries

Argentina

Australia

Bulgaria

- Canada
 - Colombia
 - Denmark
 - Greece
 - India
 - Ireland
 - Korea, Republic of
 - Kuwait
 - Mexico
 - Portugal
 - Saudi Arabia
 - Spain
 - Taiwan
 - United Arab Emirates
 - United Kingdom
 - United States
-

Study status

Planned

Research institutions and networks

Institutions

Observational & Pragmatic Research Institute Pte (OPRI)

United Kingdom

First published: 06/10/2015

Last updated: 19/08/2024

Institution

Educational Institution

Laboratory/Research/Testing facility

ENCePP partner

Contact details

Study institution contact

David Price

Study contact

dprice@opri.sg

Primary lead investigator

David Price

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 24/02/2023

Study start date

Planned: 24/02/2023

Date of final study report

Planned: 06/04/2023

Sources of funding

- Other

More details on funding

Observational and Pragmatic Research Institute UK

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Scope of the study:

Disease epidemiology

Main study objective:

To describe the cardiorespiratory impact of the COVID-19 pandemic in the UK.

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Medical condition to be studied

Chronic obstructive pulmonary disease

Myocardial infarction

Population studied

Age groups

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Estimated number of subjects

509260

Study design details

Outcomes

COPD exacerbation, with those requiring hospitalization being described separately Myocardial infarction Death

Data analysis plan

The monthly incidence rates of each outcome will be calculated separately for every month during the study period. The incidence rates will be described and visualized using histograms. Gross trends in incidence rates will be identified visually, specifically those before, during, and after the COVID-19 pandemic. The COVID-19 pandemic period will be defined using landmark dates in the UK's anti-pandemic measures, with March 2020 (when the national lockdown started) being the start of the COVID-19 pandemic period, and March 2022 (when all anti-pandemic restrictions were lifted) being the end.

Data management

Data sources

Data source(s)

Optimum Patient Care Research Database

Data sources (types)

[Electronic healthcare records \(EHR\)](#)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No